Oruka Therapeutics, Inc. (ORKA) Income Statement
ORKA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsORKA revenue and net income
ORKA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ORKA quarterly EPS vs estimates
Oruka Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.68).
ORKA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $83,000 | $27,000 | $111,000 | $114,000 | $91,000 | $93,000 | $89,000 | $22,000 | $27,000 | $24,000 |
| Gross profit | −$83,000 | −$27,000 | −$111,000 | −$114,000 | −$91,000 | −$93,000 | −$89,000 | −$22,000 | −$27,000 | −$24,000 |
| Research & development | $100.6M | $75.1M | $1.0M | $4.5M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M |
| Sales, general & admin | $21.4M | — | — | — | — | — | — | — | — | — |
| Total operating expenses | $122.0M | $88.1M | $7.2M | $9.7M | $19.2M | $9.7M | $5.7M | $8.1M | $18.7M | $16.6M |
| Operating income | −$122.1M | −$88.1M | −$7.3M | −$9.8M | −$19.3M | −$9.8M | −$5.8M | −$8.1M | −$18.7M | −$16.6M |
| Interest income | $16.6M | — | — | — | — | — | — | — | — | — |
| Interest expense | $0 | $1.5M | — | — | — | $9,000 | $7,000 | — | — | — |
| Income before taxes | −$105.4M | −$83.7M | −$5.3M | −$9.9M | −$19.3M | −$9.7M | −$5.6M | −$8.0M | −$18.6M | −$16.4M |
| Income taxes | — | — | — | — | — | −$9,000 | −$167,000 | −$31,000 | −$61,000 | — |
| Net income | −$105.4M | −$83.7M | −$5.3M | −$9.9M | −$19.3M | −$9.7M | −$5.5M | −$7.9M | −$18.5M | −$16.4M |
| EBITDA | −$105.3M | −$82.2M | −$5.2M | −$9.8M | −$19.2M | −$9.6M | −$5.6M | −$7.9M | −$18.5M | −$16.4M |
| EPS (diluted) | −$1.86 | −$4.36 | −$3.41 | −$1.01 | −$1.55 | −$2.44 | −$4.15 | −$50.03 | −$391.18 | −$391.70 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $43,000 | $43,000 | $28,000 | — | $19,000 | $16,000 | $16,000 | −$20,000 | $12,000 | $19,000 | $23,000 | $30,000 |
| Gross profit | −$43,000 | −$43,000 | −$28,000 | — | −$19,000 | −$16,000 | −$16,000 | $20,000 | −$12,000 | −$19,000 | −$23,000 | −$30,000 |
| Research & development | $43.3M | $29.1M | $27.6M | $29.0M | $24.1M | $19.9M | $32.3M | $25.7M | $18.7M | $165,000 | $47,000 | $322,000 |
| Sales, general & admin | $6.8M | $7.3M | $6.8M | $5.1M | $4.3M | $5.2M | $6.0M | $3.8M | $2.8M | $1.7M | — | — |
| Total operating expenses | $50.1M | $36.4M | $34.4M | $34.1M | $28.4M | $25.1M | $38.3M | $29.4M | $21.5M | $2.5M | $1.6M | $1.9M |
| Operating income | −$50.1M | −$36.4M | −$34.4M | −$34.1M | −$28.4M | −$25.1M | −$38.3M | −$29.4M | −$21.5M | −$2.5M | −$1.6M | −$1.9M |
| Interest income | $8.9M | $4.6M | $4.8M | $3.8M | $3.9M | $4.1M | — | $1.3M | $0 | $0 | — | — |
| Interest expense | — | — | $0 | $0 | $0 | $0 | — | $504,000 | $750,000 | $214,000 | — | — |
| Income before taxes | −$41.2M | −$31.8M | −$29.6M | −$30.3M | −$24.6M | −$21.0M | −$33.4M | −$28.6M | −$22.2M | −$2.0M | −$1.1M | −$1.4M |
| Net income | −$41.2M | −$31.8M | −$29.6M | −$30.3M | −$24.6M | −$21.0M | −$33.4M | −$28.6M | −$22.2M | −$2.0M | −$1.1M | −$1.4M |
| EBITDA | −$50.1M | −$31.8M | −$29.6M | −$30.3M | −$24.6M | −$21.0M | −$37.4M | −$28.1M | −$22.2M | −$2.0M | −$1.1M | −$1.4M |
| EPS (diluted) | −$0.55 | −$0.48 | −$0.45 | −$0.55 | −$0.46 | −$0.40 | −$0.54 | −$1.46 | −$2.22 | −$0.14 | −$0.90 | −$1.19 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ORKA's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ORKA financial results
Oruka Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $105.4 million. Diluted earnings per share came to −$1.86.
See the ORKA stock overview for the latest quote and news, or the ORKA chart for price history and technical indicators.
ORKA income statement FAQ
Does Oruka Therapeutics have revenue?
Oruka Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Oruka Therapeutics profitable?
No. Oruka Therapeutics reported a net loss of $105.4 million in fiscal 2025.
How much does Oruka Therapeutics spend on research and development?
Oruka Therapeutics spent $100.6 million on research and development in fiscal 2025.
What are Oruka Therapeutics's earnings per share?
Oruka Therapeutics earned $-1.86 per diluted share in fiscal 2025, compared with $-4.36 a year earlier.
When will Oruka Therapeutics report its next earnings?
Oruka Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Oruka Therapeutics's fiscal year end?
Oruka Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.